On 19 November 2018, orphan designation (EU/3/18/2095) was granted by the European Commission to United Neuroscience Limited, Ireland, for Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp (also known as UB-312) for the treatment of multiple system atrophy.
Treatment of multiple system atrophy
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
|April 2023||The sponsor’s address was updated.|
|May 2020||The sponsor’s address was updated.|
Documents related to this orphan designation evaluation
EU/3/18/2095: Public summary of opinion on orphan designation: Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp for the treatment of multiple system atrophy (PDF/122.22 KB)
First published: 25/02/2019
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: